Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis [0.03%]
派姆单抗诱导的葡萄膜炎的临床特征、治疗及转归
Zhaoquan Wu,Wei Sun,Chunjiang Wang
Zhaoquan Wu
Pembrolizumab has been associated with episodes of uveitis, and the clinical characteristics between them are unknown. The aim of this study was to investigate the clinical characteristics of pembrolizumab-induced uveitis and to provide ref...
Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies [0.03%]
药物增效技术在药疗中的新进展以增强药物的选择性
Helin Li,Wenjing Zhang,Qiu Meng et al.
Helin Li et al.
The therapeutic effects of many pharmacotherapies have been explored, but disadvantages such as low drug specificity, drug resistance and side effects makes their effective delivery to target sites a great challenge. Consequently, a distinc...
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system [0.03%]
基于FDA不良事件报告系统的特立帕肽上市后安全性信号的不对称分析
Chunyong Xia,Zhijing Liu,Jie Liu et al.
Chunyong Xia et al.
Background: Relugolix has been used to treat advanced prostate cancer. This study assessed adverse events (AEs) associated with relugolix from the US Food and Drug Administration Adverse Event Reporting System (FAERS). ...
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants [0.03%]
MK-1088（一种新型双腺苷受体拮抗剂）在健康成人受试者中的I期随机、对照、递增剂量的药物安全性、耐受性和药代动力学研究
Pranav Gupta,Manash Chatterjee,Yeonil Kim et al.
Pranav Gupta et al.
This phase 1 first-in-human study evaluated the safety, tolerability, and pharmacokinetics of MK-1088, a novel, small-molecule dual inhibitor of adenosine A2A and A2B receptors. Healthy adult participants were enrolled in two panels (n = 8 ...
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors [0.03%]
用于晚期实体瘤患者的普洛卡布和吉西他滨的I期安全性和有效性临床试验
Mohammad H Ghalib,Mariano Provencio Pulla,Maria J De Miguel Luken et al.
Mohammad H Ghalib et al.
Plocabulin (Plo) induces depolymerization of tubulin fibers with disorganization and fragmentation of the microtubule network leading to mitosis. Plo combined with gemcitabine (Gem) showed synergistic anti-tumor activity in preclinical stud...
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study [0.03%]
伊ринoterkan脂质体(HR070803)联合5-氟尿嘧啶和亚叶酸钙治疗晚期实体瘤的Ⅰb期剂量递增与扩展研究
Dongmei Ji,Weina Shen,Ting Li et al.
Dongmei Ji et al.
This phase 1b study aimed to evaluate the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetics, and preliminary efficacy of HR070803, a novel nanoliposomal formulation of irinotecan, in combination with 5-fluorouraci...
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else [0.03%]
纳武单抗诱导的心肌炎的临床特征、诊断和处理：过敏性心肌炎，还是其他原因所致？
Nicholas G Kounis,Virginia Mplani
Nicholas G Kounis
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer [0.03%]
TAS-102、伊立替康与贝伐单抗联合用药治疗转移性结直肠癌的二线疗效：Ⅰ期临床试验
Jing Zhang,Wenwei Yang,Junbao Liu et al.
Jing Zhang et al.
Purpose: This phase I trial is to determine the recommended dose of the TAS-102, irinotecan plus bevacizumab regimen and assess its safety and efficacy in patients with metastatic colorectal cancer refractory to fluoropyr...
Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer [0.03%]
奥拉帕利联合艾珠单抗通过促进抗肿瘤免疫反应抑制胰腺癌生长
Yanqi Zhong,Heng Zhang,Peng Wang et al.
Yanqi Zhong et al.
The present study aimed to clarify the hypothesis that auger emitter 125I particles in combination with PARP inhibitor Olaparib could inhibit pancreatic cancer progression by promoting antitumor immune response. Pancreatic cancer cell line ...
A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumor [0.03%]
一种新的同时表达凋亡素和蜂毒素基因的重组腺病毒能够杀伤肝癌细胞并抑制异位肿瘤生长
Jingqiao Wu,Zhaoyu Lan,Xin Li et al.
Jingqiao Wu et al.
HCC is the most common fatal malignancy. Although surgical resection is the primary treatment strategy, most patients are not eligible for resection due to tumor heterogeneity, underlying liver disease, or comorbidities. Therefore, this stu...